A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU
Phase of Trial: Phase IV
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Corticotropin (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Sponsors Mallinckrodt plc
- 26 Nov 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2018 According to a Mallinckrodt plc media release, first patient has been screened in the trial.
- 10 Sep 2018 New trial record